Motor assessments in HD clinical trials: Q-Motor versus the UHDRS-TMS – what did we learn from recent studies?
Objective: To review the performance of UHDRS-TMS and Q-Motor quantitative motor measures in recent placebo-controlled clinical trials. Background: The UHDRS-TMS has widely been used to…Effect of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Parkinson’s Disease Questionnaire (PDQ-39) analysis from the BIPARK-I double-blind experience
Objective: To evaluate the impact of opicapone (OPC) on PDQ-39 in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: OPC, a once-daily COMT…Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Patient and Clinical Global Impression of Change from the BIPARK-I double-blind experience
Objective: To evaluate, in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations, the patients’ and clinicians’ perception of PD symptoms improvement [as assessed by…Opicapone odds ratio in relative OFF-time reduction: a post-hoc analysis from combined BIPARK-I and II data
Objective: To evaluate the opicapone (OPC) associated patient’s odds ratio (OR) in relative OFF-time reduction. Background: OPC, a once-daily COMT inhibitor, proved effective in the…Symptomatic treatment of hereditary spastic paraplegias with fampridine: a pilot study
Objective: Study the effect of fampridine in gait outcomes in patients with hereditary spastic paraplegia (HSP). Background: Fampridine acts through blockade of voltage-gated potassium channels,…Addition of Opicapone to Safinamide in Parkinson’s Disease patients
Objective: To assess safety and efficacy of Opicapone in patients treated with Levodopa and Safinamide presenting early morning “off” states and akinesia. Background: Safinamide is…Vortioxetine treatment of depression in Parkinson’s disease
Objective: To assess efficacy and safety of Vortioxetine in Parkinson’s Disease (PD) patients affected by depression and its effects on motor performance. Background: Depression is…Influence of demographic characteristics in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate the impact of demographic characteristics in the efficacy response of levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: Opicapone (OPC), a…Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson’s disease patients: post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate the impact of motor fluctuations (MF) duration, levodopa dose and levodopa duration of use (LDU) in efficacy responses of levodopa-treated Parkinson’s Disease…Influence of baseline OFF-time in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the impact of baseline OFF-time on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: OPC,…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.